10-Q: Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics, a clinical-stage biotech company, released its Q2 2024 financial results, highlighting increased R&D spending and ongoing clinical trial progress for its lead drug candidate, EFX.

Summary

• Akero Therapeutics, a clinical-stage company focused on metabolic diseases, reported a net loss of $109.3 million for the six months ended June 30, 2024, compared to a net loss of $56.9 million for the same period in 2023.
• The company's research and development expenses increased significantly to $106.0 million for the first half of 2024, up from $49.8 million in the first half of 2023, primarily due to increased clinical trial costs.
• General and administrative expenses also rose to $19.7 million for the first half of 2024, compared to $14.6 million in the first half of 2023.
• Akero's cash, cash equivalents, and marketable securities totaled $848.3 million as of June 30, 2024, which the company believes will fund operations into the second half of 2027.
• The company is progressing its Phase 3 SYNCHRONY program for efruxifermin (EFX), its lead product candidate for MASH, and expects to report primary endpoint results from the SYNCHRONY Histology and SYNCHRONY Real-World clinical trials.
• Akero has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is progressing its clinical trials, the significant increase in net losses and the need for additional capital raise concerns. The risks associated with clinical development and regulatory approvals also temper the overall outlook.

Positives

• Akero has a strong cash position of $848.3 million, which is expected to fund operations into the second half of 2027.
• The company is actively progressing its Phase 3 SYNCHRONY program for EFX.
• Akero anticipates reporting primary endpoint results from key Phase 3 clinical trials.

Negatives

• The company experienced a significant increase in net losses, reaching $109.3 million for the first half of 2024.
• Research and development expenses have increased substantially, primarily due to ongoing clinical trials.
• Akero has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.

Risks

• Enrollment and retention of patients in clinical trials is challenging and can be affected by competition and public health crises.
• The company faces substantial competition from other pharmaceutical and biotechnology companies developing treatments for MASH.
• Failures or delays in clinical trials could increase costs and delay or prevent the company's ability to generate revenue.
• The manufacturing of product candidates is complex and may encounter difficulties, potentially delaying or stopping supply.
• Akero is heavily dependent on the success of EFX, its only product candidate.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• Akero will require additional capital to finance its operations, which may not be available on acceptable terms or at all.
• Business interruptions resulting from public health crises and geopolitical conflicts could disrupt the development of product candidates.

Future Outlook

Akero expects its existing cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of the financial statements and to fund the Phase 3 SYNCHRONY Histology and SYNCHRONY Real World studies through readout of their respective primary endpoints and to fund its current operating plan into the second half of 2027. The company also expects to continue to incur significant expenses for at least the next several years as it advances EFX through later-stage clinical development, develops additional product candidates and seeks regulatory approval of any product candidates that complete clinical development.

Management Comments

• Management believes EFX has the potential, if approved, to be an important medicine for treating MASH.
• Management expects that its existing cash, cash equivalents and shortand long-term marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these condensed consolidated financial statements.

Industry Context

The announcement comes amid a competitive landscape in the development of treatments for MASH, with several pharmaceutical and biotechnology companies also pursuing therapies for this condition. The company's focus on EFX as a potential monotherapy and its ability to address all stages of MASH pathogenesis positions it as a key player in the field.

Comparison to Industry Standards

• Akero's increased R&D spending is consistent with other clinical-stage biotech companies focused on late-stage drug development.
• The company's cash runway into the second half of 2027 is relatively strong compared to many peers, providing financial stability for ongoing clinical trials.
• The reported net losses are typical for a company at this stage of development, as revenue generation is not expected until product approval and commercialization.
• The company's focus on a single lead product candidate, EFX, is a common strategy for smaller biotech companies, but it also carries higher risk if the candidate fails to achieve regulatory approval or commercial success.
• The company's reliance on third-party manufacturers is also a common practice in the biotech industry, but it introduces supply chain risks that need to be carefully managed.

Corporate Governance

Legal Proceedings

• A purported stockholder filed a lawsuit against the company and three of its officers, alleging misstatements and omissions regarding the Phase 2b SYMMETRY study. The company intends to vigorously defend against the lawsuit.

Stakeholder Impact

• Shareholders may be concerned about the increased net losses and the need for additional capital.
• Employees may be affected by potential changes in operations or staffing due to financial constraints.
• Patients may benefit from the development of new treatments for MASH, but clinical trial delays could impact timelines.
• Suppliers and manufacturers may be affected by changes in the company's financial condition or development plans.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Continue enrollment and conduct of the Phase 3 SYNCHRONY program.
• Report primary endpoint results from the SYNCHRONY Histology and SYNCHRONY Real-World clinical trials.
• Pursue regulatory approvals for EFX, if clinical trials are successful.
• Explore potential collaborations and licensing opportunities.
• Secure additional funding to support ongoing operations and future development.

Key Dates

Keywords

Akero Therapeutics, efruxifermin, EFX, MASH, NASH, clinical trials, biotechnology, pharmaceutical, SYNCHRONY, SYMMETRY, FGF21, metabolic disease, liver disease